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Abstract
Background: Cancer metastasis is one of the most common causes of treatment failure and death in cancer
patients. It has been acknowledged that aberrant activation of epithelial-to-mesenchymal transition (EMT) program,
endows cancer cells with metastatic competence for which E-cadherin switch is a well-established hallmark.
Suppression of E-cadherin by its transcriptional repressor Slug is thus a determining factor for EMT. Here, we aimed
at discerning (i) the molecular mechanisms that regulate Slug/E-cadherin axis in oncogenic K-ras-expressing
non-small cell lung carcinoma (NSCLC) cells, and (ii) the effect of aspirin in modulating the same.
Methods: The migratory behaviour of NSCLC cell line A549 were deciphered by wound healing assay. Further
assessment of the molecular mechanisms was done by western blotting, RT-PCR, confocal microscopy, chromatin
immunoprecipitation and small interfering RNA (siRNA)-mediated gene silencing.
Results: Here we report that in oncogenic K-ras-expressing A549 cells, Ras/ERK downstream Elk-1 forms p-Elk-1-
p300 complex that being directly recruited to SLUG promoter acetylates the same to ensure p65NFκB binding for
transcriptional up-regulation of Slug, a transcriptional repressor of E-cadherin. Aspirin inhibits EMT and decelerates
the migratory potential of A549 cells by down-regulating Slug and thereby up-regulating E-cadherin. Aspirin
impedes activation and nuclear translocation of p65NFκB, essential for this transcription factor being available for
SLUG promoter binding. As a consequence, Slug transcription is down-regulated relieving A549 cells from Slug-
mediated repression of E-cadherin transcription, thereby diminishing the metastatic potential of these oncogenic
Ras-expressing NSCLC cells.
Conclusions: Cumulatively, these results signify a crucial role of the anti-inflammatory agent aspirin as a novel
negative regulator of epithelial-to-mesenchymal transition thereby suggesting its candidature as a promising tool
for deterring metastasis of highly invasive K-ras-expressing NSCLC cells.
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Background
The major cause of severity and incurability of NSCLCs
is due to establishment of cancer cells as metastatic en-
tity. The initiation of tumor metastasis involves in-
creased migratory and invasive capabilities. During
tumor progression, tumor cells acquire molecular
expression of mesenchymal markers and loss the expres-
sion of epithelial markers to result in epithe-
lial to mesenchymal transition (EMT) and subsequent
tumor metastasis [1]1. EMT is a precisely regulated
process through which epithelial cells lose polarity
and cell to cell junction and gain a fibroblast-like
morphology [2]2. An important hallmark of EMT, during
which the cell skeleton undergoes rearrangement, is the
loss of expression of the cell to cell adhesion molecule,
E-cadherin which is one of the most important indica-
tors of epithelial phenotype [3]3. E-cadherin is thus a
suppressor of invasion and metastasis and its down-
regulation provokes the development of malignant epi-
thelial cancers [4–6]456. Several developmentally import-
ant genes that induce EMT have been shown to act as
E-cadherin repressors [7]7. Suppression of E-cadherin
expression by its transcriptional suppressor—Slug plays
a crucial role in epithelial to mesenchymal transition.
Slug, a member of the Snail family of transcriptional re-
pressors, is capable of repressing E-cadherin expression
in epithelial cells via the E-box elements in the proximal
E-cadherin promoter [7]8 and thereby triggering EMT
[7–9]91011, suggesting that it may act to promote inva-
sion. Slug expression has been shown to have a strong
correlation with loss of E-cadherin in cancer cells [7]12,
suggesting Slug to be a likely in vivo repressor of E-
cadherin expression in metastatic cancers.
It is well known that, human cancers with oncogenic
mutation in Ras allele are highly aggressive and are asso-
ciated with poor prognosis. K-ras mutational status has
been found to be closely associated with both primary
tumors and metastases for more than 90 % of the pa-
tients with lung cancer [10, 11]1314. Most K-ras muta-
tions in NSCLCs have been found at codon 12 resulting
in constitutive activation of Ras proteins that regulates
cell junctions in lung epithelial cells through Cox-2 in-
duction and indulges the process of tumor metastasis
[12–14]151617. There are several reports signifying NFκB
as an important downstream target of Ras-activated sig-
nal transduction pathways [15]18. Interestingly, correl-
ation between increased activity of NFκB and expression
of K-ras has been revealed in recent years [16, 17]1920. In
fact the activity of transcriptional activation domain of
NFκB, i.e., RelA/p65 subunit, was found to be increased
significantly in Ras-transformed cells [18]21. In an onco-
genic K-ras-induced lung cancer mouse model, genetic
alteration of p65 has been found to reduce tumorigen-
esis [19]22. Arsura et al. has reported aberrant activation
of classical NFκB in Ras-transformed rat liver epithelial
cells due to increased phosphorylation and degradation
of IκBα protein [20]23. Many reports also indicate the in-
volvement of RelA/p65 in metastatic potential of tumors
[21–23]242526. According to Huber et al., while NFκB
plays a crucial role in the induction of EMT in Ras-
transformed mammary epithelial cells, blocking NFκB
activity suppresses EMT phenotype [24]27. However, the
exact molecular mechanism underlying the contribution
of p65NFκB in oncogenic K-ras-expressing NSCLC cells
invasive responses like EMT and metastasis, for which
E-cadherin is a key inhibitory factor, is yet to be
delineated.
Accumulating clinical and epidemiological evidences
also provides a quite clear and strong link between in-
flammation and cancer progression. The non-steroidal
anti-inflammatory drug aspirin is recently being reported
to reduce risk of cancer initiation and progression and
suggested to be used to target several tumor properties,
including tumor cell migration [25]28. Regular use of as-
pirin has also been observed to decrease the risk of non-
small cell lung carcinoma [26–28]293031, thereby suggest-
ing that NSCLCs could be targeted by using aspirin.
However, there is no detailed study on the anti-
migratory role of aspirin in EMT and NSCLC cells'
migration.
In a recent study, using paired colon cancer cell lines
that differ in the expression of mutant K-ras, Wang et al.
[29]32 identified that Slug is selectively required for the
survival of cancer cells with mutant K-ras. They further
showed that Slug is regulated by the Ras pathway and is
very important for activated Ras induced EMT. This and
other findings support Slug as a target for treatment of a
broad spectrum of human cancers that have undergone
EMT, associated at least in part with mutational activa-
tion of Ras [30]33.
This study elaborates that Ras-down-stream Elk-1-
p300 complex acetylates and unwinds SLUG promoter
to make it accessible for p65NFκB binding which is a
pre-requisite for Slug transcription that subsequently
leads to E-cadherin down-regulation. Further explor-
ation focuses on the role of anti-inflammatory agent as-
pirin in up-regulating E-cadherin to inhibit EMT in
oncogenic K-ras-expressing NSCLC cells, A549. In gist,
aspirin represses the expression of Slug, a known nega-
tive regulator of E-cadherin, by blocking the activation
of p65 subunit of NFκB and its translocation to nucleus.
As a result, E-cadherin gets up-regulated which in turn
decelerates the metastatic potential of these highly meta-
static NSCLC cells. We therefore, project FDA-approved
anti-inflammatory drug aspirin as a novel negative regu-
lator of epithelial-to-mesenchymal transition, thereby
signifying its candidature for deterring cancer
metastasis.
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Results
Oncogenic K-ras induces a pro-invasive EMT phenotype in
NSCLC cells in a Slug-dependent pathway involving E-
cadherin suppression
We first sought to evaluate the effects of oncogenic K-
ras on the migratory response of wild-type p53-
expressing NSCLC cells. To this end, we used A549 cells
having K-ras mutation at codon 12 which is responsible
for its oncogenic property, and compared its migratory
potential with wild type K-ras-bearing H1299 cells that
were p53-reconstituted (p53+/+). Results of wound heal-
ing assay showed higher migratory potential of A549
cells than p53-reconstituted H1299 cells (Fig. 1a) sug-
gesting that the metastasizing capacity of cancer cells
might be dependent on K-ras status, since all other con-
ditions were same in the two cell lines. Validating this
hypothesis, when dominant negative (DN) mutant form
of RAS (N17-NRAS) was introduced in A549 cells
(Fig. 1b, right panel), reduction in the migratory capacity
of these transfectants was observed as compared to par-
ental cells (Fig. 1b, left and middle panels). These results
together confirm the contribution of oncogenic K-ras in
migration of NSCLC cells. In addition to oncogenic K-
ras, mutated p53 are also reported to correlate with
metastatic phenotype and play gain-of-function role in
oncogenesis. In line with this, two p53 mutants that are
commonly found in human cancer and that have been
extensively used to study role of p53, in cell migration
are R273H (R270H in mice), which directly compro-
mises DNA binding, and R175H (R172H in mice), which
causes a global conformational distortion of p53 [31]34.
These mutations inhibit p53’s ability to act as a tran-
scription factor, accounting for their reduced ability to
function as tumor suppressors. For this, to further check
the role of mutant p53 in migration of NSCLCs, onco-
genic K-ras expressing mutant p53 bearing NSCLC cell
line NCI-H522 was used for wound healing migration
assay (Additional file 1: Figure S1). Along with this,
H1299 cells were transfected with p53 R175H clone
(wild type K-ras mutated p53 system) and performed
for wound healing assay. Conjointly our data revealed
that presence of both oncogenic K-ras and p53 shows
highest migratory capacity followed by oncogenic K-ras
expressing NSCLCs. Migration potential of mutant p53
follows migration potential of oncogenic K-ras express-
ing NSCLCs. However, the lowest migration potential
among the four sets is showed by wild type p53 express-
ing wild type Ras bearing sample. This in turn indicates
that oncogenic K-ras accelerates the capacity of mutant
p53 to induce migration.
Next, we attempted to investigate the mechanism
underneath oncogenic K-ras-induced NSCLC cells mi-
gration. For the same, we compared the expression of
the well known epithelial marker E-cadherin in
oncogenic K-ras-bearing parental A549 cells and DN-K-
ras reconstituted A549 cells, since loss of E-cadherin has
been reported to endorse tumor metastasis [32]35. Con-
vincingly, confocal images revealed increase in E-
cadherin expression in DN-K-ras reconstituted A549
cells as compared to the parental oncogenic K-ras-
expressing A549 cells (Fig. 1c, upper panel). In line with
this, RT-PCR (Fig. 1c, lower left panel) and western blot
(Fig. 1c, lower right panel) experiments further showed
that in contrast to A549 cells, E-cadherin expression in-
creased in DN-K-ras-reconstituted A549 cells. Role of E-
cadherin in K-ras mediated retardation of NSCLCs mi-
gration was re-confirmed when E-cadherin-siRNA
transfected-A549 cells exhibited increased migration
over control siRNA-transfected cells (Fig. 1d).
Next, we aimed at exploring the molecular mechanism
underneath oncogenic K-ras-mediated inhibition of E-
cadherin. Multiple evidences indicate that the metastatic
spread of cancer cells is strongly regulated by Slug, a
transcriptional repressor of E-cadherin [32]36. To evalu-
ate if Slug-dependent E-cadherin repression is relevant
for oncogenic K-ras-induced invasiveness, we correlated
the levels of Slug expression to K-ras status in parental
as well as DN-K-ras-transfected A549 cells. Results of
Fig. 1e depicted reduced expression of Slug both at tran-
scriptional (Fig. 1e, upper panel) and translational
(Fig. 1e, lower panel) levels in A549 cells with DN-K-ras
when compared to parental A549 cells, while silencing
Slug (Fig. 1f, right panel) restored E-cadherin levels at
both mRNA (Fig. 1f, upper left panel) and protein levels
(Fig. 1f, lower left panel), thereby further validating our
hypothesis. In a parallel experiment, transfection of DN-
K-ras in Slug-silenced (Fig. 1f, right panel) set reduced
migration than the control ones (Fig. 1f, middle panel),
thereby indicating that oncogenic K-ras uses Slug to in-
duce malignant cell responses.
Oncogenic K-ras induced migration occurs through tran-
scriptional up-regulation of Slug
From previous results we hypothesized that, onco-
genic K-ras induces migration through up-regulation
of Slug. To further investigate the complete signalling
pathway up-stream of Slug, we studied downstream
components of Ras/Raf/MEK/ERK pathway, MEK and
ERK, and silenced them individually with MEK-siRNA
(Fig. 2a, upper right panel) and ERK-siRNA (Fig. 2a,
lower right panel), respectively, in oncogenic K-ras-
bearing A549 cells. Both the transfectants showed in-
creased expression of E-cadherin as well as decreased
expression of Slug than control A549 cells, at both
mRNA (Fig. 2a, upper left panel) and protein (Fig. 2a,
lower left panel) levels. In line with this, percent cell
migration was lower for MEK-siRNA- or ERK-siRNA-
transfected A549 cells than control ones (Fig. 2b).
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Fig. 1 E-cadherin-Slug axis regulates NSCLC cells migration in oncogenic K-ras expressing system. a Phase contrast images depicting migration of A549
cells (upper left panel) and p53-reconstituted H1299 cells (lower left panel) for up to 24 h was determined by wound healing assay and percent cell
migration was represented graphically (right panel). Scale bar: 100 μm. The inset shows immunoblot analysis for the transfection efficiency of p53-cDNA in
H1299 cells. b Phase contrast images depict time-dependent migration of oncogenic K-ras expressing control (upper left panel) and DN-K-ras-transfected
A549 cells (lower left panel) as determined by wound healing assay and percent cell migration was quantified and represented graphically (right panel).
Scale bar: 100 μm. The immunoblot analysis of p-MEK depicts the transfection efficiency of DN-K-ras-cDNA in A549 cells (inset). c Upper panel: Expression
of E-cadherin was visualised by immunofluorescence in control and DN-K-ras-transfected A549 cells (Scale bar: 10 μm). Images were counterstained with
DAPI to represent nuclei. Lower panel: mRNA (left panel) and protein (right panel) expression levels of E-cadherin in control and DN-K-ras-transfected A549
cells as determined by RT-PCR and western blot analyses, respectively. d Percent cell migration of untransfected-/ E-cadherin-siRNA transfected, oncogenic
K-ras-expressing control and DN-K-ras-reconstituted-A549 cells as determined by wound healing assay was quantified and represented graphically. The
inset represents the immunoblot analysis for the transfection efficiency of E-cadherin-siRNA. e Expression profiles of Slug mRNA (upper panel) and protein
(lower panel) levels of control and DN-K-ras-transfected A549 cells as determined by RT-PCR and western blot analyses, respectively. fmRNA (upper left
panel) and protein (lower left panel) expression levels of E-cadherin in untransfected-/ Slug-siRNA transfected control and DN-K-ras-reconstituted A549 cells
as determined by RT-PCR and western blot analyses, respectively. Graphical representations of percent cell migration for the same experimental set as
determined by wound healing assay (right panel). The inset represents the immunoblot analysis for the transfection efficiency of Slug-siRNA. α-Actin/
GAPDH was used as an internal loading control. Data are presented as mean ± SEM or representative of three independent experiments
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Fig. 2 (See legend on next page.)
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Interestingly, although silencing MEK/ERK led to
Slug down-regulation, neither MEK nor ERK has any
DNA-binding domains and, therefore, is not consid-
ered as transcription factors [33]37. Considering this
information, we next searched for the contribution
of another downstream transcription factor and ob-
served the contribution of Elk-1, a direct substrate
of ERK [34]38, in Slug repression. Moreover, the ETS
family transcription factor Elk-1 is known as the
downstream effecter molecule of all three MAPK
pathways, i.e. p38 MAPK, JNK and ERK pathways but
through different residues [35]39. ERK can bind to
Elk-1 in the D-domain, which is located N-terminal
from the C-terminal transcriptional domain (C-do-
main), and phosphorylate S383 and S389 in this do-
main [36]40. ERK-induced Elk-1 phosphorylation
leads to enhanced DNA-binding and TCF-mediated
transcriptional activation [37]41. Therefore, in our
system, we designed battery of overlapping primer
sets for SLUG promoter (Fig. 2c) and our chromatin
immunoprecipitation (ChIP) assay demonstrated four
putative binding sites of Elk-1 on the SLUG pro-
moter, two on promoter 1 (−329 to −228 and −265
to −129) (Fig. 2d, upper panel) and two on promoter
2 (−496 to −384 and −181 to −40) (Fig. 2d, lower
panel). Further search showed that in comparison to
the control cells, Elk-1 expression did not show any
significant change while the activation of Elk-1 was
decreased in both DN-K-ras-expressing, MEK-
siRNA-transfected and ERK-siRNA-transfected A549
cells (Fig. 2e, left panel). Since the changes in pho-
phorylation of Elk-1 are relatively small, densitomet-
ric analysis of the same was represented in the right
panel of Fig. 2e. In our next experiment, binding of
p-Elk-1 on SLUG promoter was found to be de-
creased in DN-K-ras-reconstituted A549 cells than
oncogenic K-ras-expressing control A549 cells
(Fig. 2f ). In keeping with our previous experiment
where DN-K-ras-reconstituted A549 cells showed
down-regulation of Slug mRNA levels than the con-
trol ones (Fig. 1e), these results directly proved the
role of K-ras-downstream p-Elk-1 for Slug up-
regulation.
Oncogenic K-ras in association with p65NFκB, up-
regulates Slug transcription in A549 cells
It has been documented that in A549 cells, p65NFκB is
over-expressed [38]42 and p65/RelA subunit of NFκB is
functionally activated by Ras for efficiently promoting
tumorigenesis [39]43. A very recent report also indicates
binding of p65NFκB on SLUG promoter in A549 cells
[40]44. Keeping these in mind, we next aimed at deter-
mining whether the interaction between Elk-1 and
p65NFκB influences Slug expression and the mechanism
behind it. Our search revealed four putative p65NFκB
binding sites adjacent to p-Elk binding sites on SLUG
promoter (Fig. 3a). We further aimed at verifying
whether absence of oncogenic K-ras hampers binding of
p65NFκB to SLUG promoter or not. Our ChIP analysis
showed inhibition in p65NFκB binding in DN-K-ras
reconstituted set (Fig. 3b). Next to check whether bindings
of both oncogenic K-ras and p65NFκB are essential for
Slug transcription to occur, we inhibited p65NFκB nuclear
translocation by transfecting A549 cells with IκBα-SR-
cDNA or silenced Elk-1-upstream ERK by transfecting
A549 cells with ERK-siRNA (Fig. 3c). In both the cases,
Slug transcription was found to be down-regulated simi-
larly than control A549 cells (Fig. 3c). These results depict
that the presence of both active p65NFκB and p-Elk-1 is
pre-requisite for Slug expression to occur.
To understand the exact molecular mechanism
underlying chromatin modification in our system, we
checked the acetylation status of SLUG promoter
under different conditions. To that end, either DN-K-
(See figure on previous page.)
Fig. 2 Oncogenic K-ras up-regulates Slug transcriptionally to induce migration in A549 cells. a mRNA (upper panel) and protein (lower panel)
expression levels of E-cadherin and Slug in untransfected-/ MEK-siRNA-/ ERK-siRNA-transfected A549 cells as determined by RT-PCR and western
blot analyses, respectively. The inset represents the immunoblot analysis for the transfection efficiency of MEK-siRNA and ERK-siRNA in A549 cells.
b Phase contrast images depicting migration of untransfected (upper left panel), MEK-siRNA-(middle left panel) and ERK-siRNA-(lower left panel)
transfected A549 cells at 24 h as determined by wound healing assay was quantified and represented graphically (right panel). c Schematic
diagram representing different regions of SLUG promoter and Slug coding region, and the sequential order of primer sets (sets 1–5 for promoter
set 1 in upper panel and primer sets 1–7 for promoter set 2 in lower panel) to identify p-Elk-1 binding regions on SLUG promoter by ChIP analysis.
d Schematic representations and RT-PCR data showing p-Elk-1-occupied region on SLUG promoter 1 (−325 to −129; primer sets 3 and 4) and
SLUG promoter 2 (−496 to −384 and −181 to −40; primer sets 1 and 5, respectively) in A549 cells as determined by ChIP analysis. e Graphical
representation of quantified relative protein expression of p-Elk-1 in untransfected, DN-K-ras-cDNA/MEK-siRNA/ERK-siRNA transfected A549 cells
(right pannel) as determined by western blot analysis of Elk-1 and p-Elk-1 (left pannel) (f) Chromatin from oncogenic K-ras expressing control
A549 cells, control-cDNA-/ DN-K-ras-transfected A549 cells was immunoprecipitated with p-Elk-1 antibody. PCR amplification was performed for
p-Elk-1 binding regions on the SLUG promoter 1 (upper panel) and SLUG promoter 2 (lower panel). α-Actin/ GAPDH served as loading controls.
Data are presented as mean ± SEM or representative of three independent experiments
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ras or IκBα-SR-cDNA was transfected individually or
in combination. In the control cells, where both
oncogenic K-ras and p65NFκB were present, and in
IκBα-SR-cDNA-transfected sets acetylation of SLUG
promoter was observed. However, in cells transfected
with DN-K-ras alone or in combination with IκBα-
SR-cDNA, no acetylation of SLUG promoter could be
seen (Fig. 3d). Since, in DN-K-ras transfected set,
Fig. 3 Slug up-regulation in A549 cells occur conjointly with oncogenic K-ras and p65NFκB pathways. a Schematic representations (upper panels) and
RT-PCR data (lower panel) of p65NFκB-occupied region on SLUG promoter 1 (−329 to −129; primer sets 3 and 4) and SLUG promoter 2 (−496 to −384 and
−181 to −40; primer sets 1 and 5, respectively) in A549 cells as determined by ChIP analysis. Lane 1 denotes input control and parallel immunoprecipitation
with control IgG antibody is shown in lane 2. b Chromatin from oncogenic K-ras expressing control A549 cells, control-cDNA-/ DN-K-ras-transfected A549
cells was immunoprecipitated with p65NFκB antibody. PCR amplification was performed on p65NFκB binding regions on the SLUG promoter 1 (upper left
panel) and SLUG promoter 2 (upper right panel). Lane 1, 2 and 3 denotes input control and parallel immunoprecipitation with control IgG antibody is
shown in lane 4, 5 and 6. (c) RT-PCR analysis for Slug mRNA levels in untransfected, ERK-siRNA-/ IκBα-SR-cDNA-transfected A549 cells and in A549 cells
transfected with both ERK-siRNA and IκBα-SR-cDNA. The inset shows the immunoblot analysis of nuclear p65NFκB levels for the transfection efficiency of
IκBα-SR-cDNA. d ChIP assay for p300 binding on the SLUG promoters 1 and 2 in untransfected, DN-K-ras-/IκBα-SR-cDNA transfected A549 cells and in
A549 cells transfected with both DN-K-ras and IκBα-SR-cDNA. e Nuclear lysates of oncogenic K-ras expressing A549 cells and DN-K-ras-transfected A549
cells was subjected to immunoprecipitation using anti-p300 antibody or with control IgG. The same blot was sequentially probed with p-Elk-1 and
p300-specific antibodies. To confirm comparable protein input of the respective samples following, 20 % of lysates used for immunoprecipitation were
subjected to western blot analysis with anti-α-Actin. Data are presented as mean ± SEM or representative of three independent experiments
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chromatin acetylation was absent and p65NFκB bind-
ing was hampered, these results highlighted that p-
Elk1 is responsible for chromatin acetylation and thus
for p65NFκB binding on SLUG promoter.
Since, Elk-1 is reported to form a pre-assembled
complex with p300 and p300 acts like a co-activator
in complexes that contain Elk-1, we proposed that in
our system Elk-1 recruits p300 to acetylate SLUG
promoter. Our co-immunoprecipitation experiment
with p-Elk-1 and p300 confirmed our hypothesis
(Fig. 3e). All these results further validated the co-
operation of p-Elk-1 and p65NFκB for Slug up-
regulation. Moreover, the parallel between gain of
anti-migratory functions of oncogenic K-ras and
p65NFκB is compatible with the concept of mutant
K-ras acting as a promoting factor for the tumor mi-
gratory activity of p65NFκB.
Aspirin inhibits migration through down-regulation of
Slug and up-regulation of E-cadherin
We next aimed to use FDA approved non-steroidal anti-
inflammatory drug aspirin, which is a known p65NFκB
inhibitor [41, 42]4546 and is reported to reduce risk for can-
cer initiation and progression to its users [43–45]474849.
Additionally, several reports suggest that aspirin could be
targeted for several other tumor properties including
tumor migration [46–48]505152. However, there are no de-
tail studies indicating anti-migratory role of aspirin on
NSCLCs.
Interestingly, results of Fig. 4a depicted decrease in
percent cell migration with increasing doses of aspirin
(0, 0.5, 2.5 and 5 mM). Since, recent report indicates
that aspirin reaches human plasma level at only 2.5 mM
concentration [49]53; we used same concentration for
our further experiments. Importantly, this dose was ob-
served to be non-toxic towards normal cell like PBMCs
(Fig. 4b), thereby verifying this as the effective non-toxic
anti-migratory dose of aspirin. Results of Fig. 4c further
showed the time-dependence of the anti-migratory effect
of aspirin 2.5 mM concentration. Interestingly, 2.5 mM
of aspirin was also found to be non-toxic for upto 24 h
(Fig. 4d).
Next, to explore whether this aspirin-induced anti-
migratory effect is mediated by Slug/E-cadherin axis,
we performed RT-PCR and western blotting for E-
cadherin and Slug with or without 2.5 mM dose of
aspirin (Fig. 4e). Interestingly, while expressions of
both E-cadherin mRNA (Fig. 4e, left panel) and pro-
tein (Fig. 4e, right panel) were induced upon aspirin
treatment, those of Slug were decreased in aspirin-
treated sets (Fig. 4e). In addition, expressions of
other EMT marker proteins, vimentin, twist, MMP-2
and MMP-9, were down-regulated by aspirin (Fig. 4f ).
These results together indicated that the non-toxic
anti-migratory dose of aspirin induced epithelial
markers and consequently repressed mesenchymal
markers to restrain migration of A549 cells.
Aspirin ensures Slug down regulation by inhibiting
p65NFκB - nuclear translocation
NFκB plays a central and evolutionarily conserved role
in coordinating the expression of various soluble pro-
inflammatory mediators and leukocyte adhesion mole-
cules. Several reports suggest that aspirin impedes can-
cer initiation and progression by inhibiting activation of
NFκB pathway [50]54. Results of Fig. 5a demonstrated
reduction in phosphorylation of IκBα upon aspirin treat-
ment, total p65NFκB expression remaining same. This
indulged us to further investigate whether aspirin con-
strains nuclear translocation of p65NFκB or not. Next in
Fig. 5b we observed reduced nuclear expression of
p65NFκB with increase in its cytosolic expression in
A549 cells upon aspirin treatment (Fig. 5b). These re-
sults together highlight that aspirin treatment impedes
activation and therefore nuclear translocation of
p65NFκB in A549 cells.
Concurrently, ChIP analysis further depicted reduced
binding of p65NFκB on SLUG promoter in aspirin-
treated A549 cells as compared to the untreated ones
(Fig. 5c). These results in correlation with our previous
data suggest that aspirin retracts p65 NFκB-induced Slug
transcription thereby inhibiting NSCLC cells migration.
In summary, Aspirin works to ensure Slug down-
regulation by restraining NFκB nuclear translocation, a
pre-requisite for SLUG promoter activation, in onco-
genic K-ras expressing NSCLCs.
Discussion
The disappearance of epithelial phenotype and acquisi-
tion of mesenchymal phenotype constitute the basic mo-
lecular and morphological manifestations of EMT. This
process increases cell mobility and constitutes a critical
step in cell migration, which is associated with various
biological processes, including cancer invasion and me-
tastasis. Thus, the maintenance of epithelial phenotype
and suppression of EMT have been increasingly recog-
nized to be important for preventing cancer progression.
During the execution of the EMT program many genes
involved in cell adhesion, migration and invasion are
transcriptionally altered, E-cadherin being one of the
most important [51]55. Since E-cadherin functions as a
key gatekeeper of the epithelial state, the partial loss of
E-cadherin has been associated with carcinoma progres-
sion and poor prognosis in various human and mouse
tumors [52]56. Evaluation of the molecular mechanisms
involved in regulation of E-cadherin expression, there-
fore, might be a critical step in controlling EMT. Our
present study has been mainly focused on the regulation
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of EMT by altering E-cadherin expression by the NSAID
aspirin in oncogenic Ras-expressing NSCLC cells. As-
pirin enhanced E-cadherin expression, which was con-
jointly associated with a loss in the migratory potential
of these cells, via down-regulation of E-cadherin repres-
sor Slug by inhibition of p65NFκB activation and its
translocation to nucleus for SLUG promoter binding.
Our effort to explore the effects of oncogenic K-ras in
aggravation of migration of NSCLC cells revealed that
oncogenic K-ras-bearing NSCLCs induce migration via
Slug/E-cadherin axis. In line with these findings there
are reports describing that expression of oncogenic K-
ras induces EMT and confers a metastatic phenotype on
carcinomas by repressing the E-cadherin gene at the
transcriptional level [53]57. Consistently, Shin et al. has
demonstrated the implication of Ras-ERK signaling in
Ras-induced transformation of epithelial cells into mes-
enchymal cells [54]58. Our results also showed that Ras/
Raf downstream effector molecule Elk-1 plays a crucial
role in NSCLC cells migration. In depth analysis denoted
that Elk-1 gets activated by Ras/Raf/ERK pathway and
forms a complex with p300 to acetylate SLUG promoter,
thereby accelerating transcriptional activation of Slug.
Supporting our observation, report of Li et al. evidenced
that Elk-1 forms pre-assembled Elk-1-p300 complex
which become active following phosphorylation of Elk-1
to ultimately lead to target gene transcription [55]59.
That Elk-1 can interact with p300 both in vitro and in
vivo through the C-terminus of Elk-1 and the N-
terminus of p300 has already been documented [55]60.
Such changes in interaction render a strong histone ace-
tyltransferase activity in the Elk-1-associated complex
Fig. 4 Aspirin retards migration of A549 cells by restoration of E-cadherin expression. a Phase contrast images depicts migration of A549 cells
upon 24 h treatment with aspirin in a dose-dependent manner (left panel) was determined by wound healing assay and percent cell migration
was represented graphically (right panel). Scale bar: 100 μm. b Graphical representation of percent cell death in PBMCs upon treatment with
aspirin in a dose-dependent manner. c Phase contrast images depicting migration of untreated (upper left panel) and aspirin (2.5 mM)-treated
(lower left panel) A549 cells in a time-dependent manner was determined by wound healing assay and percent cell migration was represented
graphically (right panel). Scale bar: 100 μm. d Graphical representation of percent cell death in PBMCs upon treatment with 2.5 mM aspirin in a
time-dependent manner. e Expression profiles of E-cadherin and Slug mRNA (left panel) and protein (right panel) levels of A549 cells upon
treatment with aspirin in a time dependent manner as determined by RT-PCR and western blot analysis, respectively. f Protein expression profiles
of migration related markers, Vimentin, Twist, MMP-2 and MMP-9 in untreated and aspirin-treated A549 cells as determined by western blot
analysis. α-Actin/ GAPDH served as loading controls. Data are presented as mean ± SEM or representative of three independent experiments
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that could play a critical role in chromatin remodelling
and gene activation [55]61.
In previous studies, it has been revealed that in onco-
genic K-ras-induced lung cancer mouse model, genetic
alteration of p65 subunit of NFκB reduces tumorigenesis
(19)62 thereby substantiating the contribution of
p65NFκB in activated Ras-induced tumor formation. In-
deed, genetic alteration of p65 leads to the tumor regres-
sion in K-ras-driven mouse tumor models [19]63. In
contrast, activity of transcriptional active domain, i.e.,
p65NFκB, was found to be increased strikingly in Ras/
Raf-transformed cells [20]64. However, such mutual
interaction between the two oncogenic pathways in pro-
moting cancer cell migration is yet to be revealed. Given
that oncogenic K-ras mutations co-exist with p65NFκB
over expression in A549 cells [38]65, we postulated that
K-ras/NFκB axis might be an important target to curb
migration in these NSCLC cells. Our findings that
p65NFκB plays a pivotal role as a transcription factor to
up-regulate Slug transcription for migration of onco-
genic K-ras-expressing A549 cells indicated the possibil-
ity of EMT being regulated by the conjoint effort of
both K-ras and p65NFκB pathways in these cells. While
K-ras pathway brings about the acetylation of the SLUG
promoter, commencement of Slug transcription occurs
only through the binding of the transcription factor
p65NFκB. Reports are there in support of Slug activation
by NFκB to confer resistance to TNF-α-induced apop-
tosis in A549 cells [56]66. Further support comes from
the role played by IKKα, inhibitor of NFκB that controls
canonical TGFβ–SMAD signaling to regulate genes ex-
pressing Snail and Slug during EMT in pancreatic cancer
cell line [57]67. Several other findings together with these
suggest Slug as a molecular platform or a target for
treatment of a range of metastatic cancers associated
with mutational Ras.
The present study further signifies the effect of FDA-
approved non-steroidal anti-inflammatory drug aspirin
on highly invasive and migratory NSCLC cell line A549.
Aspirin, i.e., acetyl salicylic acid, is known for decades to
inhibit transcription of several genes including adhesion
molecules and nitric oxides, which are known to regu-
late inflammatory pathways [58]68. One of such well
studied targets of aspirin is p65NFκB [50]69, activation
of which is associated with tumor progression and me-
tastasis of several human tumor types [59]70. Yet, the ef-
fect of aspirin on the activation of p65NFκB differs
according to cell type. Present study discusses the anti-
Fig. 5 Aspirin retards p65NFκB-nuclear translocation to ensure Slug down-regulation. a Western blot analysis to determine p-IκBα and total
p65NFκB expression levels in untreated and aspirin treated-A549 cells. b Protein expression levels of p65NFκB in nuclear and cytosolic lysates of
untreated and aspirin treated-A549 cells as determined by western blot assay. c ChIP assay for p65NFκB binding on the SLUG promoter 1 (upper
panel) and 2 (lower panel) in untreated and aspirin treated-A549 cells. α-Actin/ Histone H1 served as loading controls. Data are presented as
mean ± SEM or representative of three independent experiments
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migratory effect of this anti-inflammatory drug on lung
epithelial cell A549. We observed that aspirin inhibits
A549 cell migration by suppressing p65NFκB activation
and translocation to the nucleus for binding to SLUG
promoter, thereby resulting in the transcriptional down-
regulation of Slug in these NSCLC cells. Our observa-
tion that aspirin restrains constitutively active NFκB in
lung cancer cells concurs with recent studies demon-
strating that aspirin can also inhibit inducible p65NFκB
in cervical cancer and hepatoma cells [60]71.
Collectively, this study provides a complex molecular
framework involving p65NFκB during MEK/ERK-medi-
ated EMT. In that molecular network, p-Elk-1-p300
complex induces histone acetylation and unwinding of
SLUG promoter to make access for NFκB on the same.
Binding of p65NFκB on SLUG promoter, in turn, en-
sures Slug transcriptional up- regulation and subsequent
Slug-dependent E-cadherin repression. In contrast, as-
pirin impedes nuclear translocation of p65NFκB thereby
repressing Slug and consequently restoring E-cadherin
levels. Therefore, by modulating the pro-migratory mo-
lecular architecture, aspirin nullifies the effect of onco-
genic Ras-induced migration of NSCLCs. Altogether this
study highlights the complexity of gene-regulation and
demonstrates how aspirin abrogates effectors of EMT
such as K-ras, which, via epigenetic alterations through a
well-known MEK/ERK pathway, adds to p65NFκB func-
tions to cause tumor metastasis (Fig. 6). Such activities
of aspirin strongly support its candidature as a potential
anti-migratory agent, suggesting the possibility of devel-
opment of a treatment regimen in future for highly
metastatic non-small cell lung carcinoma.
Conclusion
This preclinical study suggests aspirin as a potent anti-
migratory agent to improve the therapeutic index of
highly metastatic NSCLCs in which EMT, a pre-requisite
for cancer cell migration, being programmed by the
Fig. 6 Schematic illustration depicts the potential role of aspirin in reprogramming EMT in oncogenic K-ras-expressing NSCLC cells. Left panel
demonstrates the conjoint role of K-ras and NFκB pathways in up-regulation of Slug transcription towards EMT in NSCLC cells. Right panel shows
aspirin-mediated inhibition of EMT and migration of NSCLC cells through inhibition of p65NFκB nuclear translocation that resulted in down-regulation of
Slug, a transcriptional repressor of E-cadherin
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conjoint effort of both K-ras and NFκB pathways. As-
pirin inhibited EMT and delayed migration of oncogenic
K-ras-expressing NSCLC cells through inhibition of
p65NFκB nuclear translocation that resulted in down-
regulation of Slug, a transcriptional repressor of E-
cadherin. Knowledge gathered from this study may open
a new avenue in future for developing more effective
treatment strategy for controlling highly invasive
NSCLCs with oncogenic K-ras.
Methods
Cell culture and treatments
The non small cell lung cancer cell line A549 (K-ras v-
12 mutated) H1299 and NCI-H522 were obtained from
National Centre for Cell Science, Pune, India. The cells
were routinely maintained in complete Dulbecco’s modi-
fied Eagle’s medium at 37 °C in a humidified incubator
containing 5 % CO2 [61]
72. Cells were allowed to reach
confluency before use. Viable cell numbers were deter-
mined by Trypan blue exclusion test. Since this study in-
volved only human cell lines and no human or animal
participants or tissues, ethical clearance was not
required.
Treatment of cells
Exponentially growing human non-small cell lung car-
cinoma cell line-A549 were seeded at a density of
2.5x106 cells/100 mm culture dishes (Becton Dickinson,
Franklin Lakes, NJ) 24 h before aspirin treatment. Cells
were treated with different concentrations of aspirin
(Acetyl Salicylic Acid from MP Biomedicals) for different
time points to select the optimum dose and time re-
quired to reduce cancer cell migration. 1 M stock solu-
tion of aspirin was prepared in DMSO and stored at −20
°C. Now, to reach final concentrations of 0.5, 2.5 or
5 mM of aspirin, 0.5 μL, 2.5 μL or 5 μL of stock solution
was added, respectively, in 1 ml cell culture media. An
equivalent amount of carrier (DMSO) was added to un-
treated cells as control to ensure that the observed effect
was related to aspirin and not due to the solvent.
Wound healing assay
Cell migration was determined by means of bidirectional
wound healing assay as described [62]73. Briefly, cells
were grown to confluency in 12 well plates after which a
sterile blade was used to scratch the monolayer of cells
to form a bidirectional wound. Migration was quanti-
tated by a semi-automated, computer-assisted procedure
by a person blinded with respect to the experimental
treatment. The data from triplicate wells were calculated
as the mean ± S.E.M., the migration rate of control cells
was taken as 100 % and healing rate of other plates were
compared with control cells.
Immunofluorescence
For immunofluorescence, cells were grown on sterile
glass coverslips at 37 °C for 24 h. Cells after treat-
ment were washed briefly with PBS and fixed with
4 % formaldehyde for 20 min at 37 °C. Thereafter,
cells were blocked for 2 h in a blocking buffer (10 %
BSA in PBS) and then additionally incubated for an-
other hour in PBS with 1.5 % BSA containing anti-
E-cadherin antibody (Santa Cruz, CA, USA). After
washing in PBS, cells were incubated with PE conju-
gated secondary antibody in PBS with 1.5 % BSA for
45 min at 37 °C in the dark. DAPI was used for nu-
clear staining. Coverslips were washed with PBS and
mounted on microscopy glass slides with 90 % gly-
cerol in PBS. Images were acquired using a confocal
microscope (Carl Zeiss, Jena, Germany) [63]74.
Immunoblotting and co-immunoprecipitation
To obtain whole cell lysates, cells were homogenized in
lysis buffer (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM
MgCl2, 1 mM Na-EDTA, 1 mM Na-EGTA and 1 mM
DTT) supplemented with protease and phosphatase in-
hibitor cocktails [64, 65]7576. For direct western blot ana-
lysis, a total of 50 μg of protein was resolved using SDS-
PAGE and transferred to nitrocellulose membrane and
probed with specific antibodies, for example, anti-
NFκB/-IκB/-slug/-E-cadherin/-MEK/-ERK/-Elk-1/-p-
Elk-1/-p53(DO-1)/-p53(FL-393) antibodies (Santa Cruz,
CA, USA), thereafter the immunoblots were visualized
by chemiluminescence (GE Biosciences, NJ, USA). To
study the interaction between Elk1 and p300, p300
immunocomplex from whole cell lysate was purified
using p300 antibody and protein A-Sepharose beads
(Invitrogen, MD). The immunopurified protein was
immunoblotted with Elk-1 antibody. The protein of
interest was visualized by chemiluminescence. Equal
protein loading was confirmed with anti-α-actin and his-
tone H1 antibodies (Santa Cruz, CA, USA) [66]77.
RT–PCR assay
Two microgram of the total RNA, extracted from cells
with TRIzol Q16 reagent (Invitrogen, Carlsbad) was re-
verse transcribed and then subjected to PCR with en-
zymes and reagents of the RTplusPCR system
(Eppendorf, Hamburg, Germany) using GeneAmpPCR
2720 (Applied Biosystems, CA, USA). The cDNAs




3′), GAPDH (internal control): (5′-CAGAACATCATCCT
GCCTCT-3′/5′-GCTTGACAAAGTG GTCGTTGAG-3′)
[67, 68]7879.
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Plasmids, siRNA and transfections
The expression constructs p53-cDNA, p53-R175H
cDNA (kind gift from Moshe Oren, Weizmann Insti-
tute of Science), N17-NRas, IκB-SR and control
pcDNA3.0 vectors (2 μg/million cells) were intro-
duced into exponentially growing cells using
lipofectamine-2000 (Invitrogen, Carlsbad) according
to the protocol provided by the manufacturer. Stably
expressing clones were isolated by limiting dilution
and selection with G418 sulfate (1 mg/ml; Cellgro)
and G418 resistant cells were cloned and screened
by immunoflourescence or western blotting with
specific antibodies. For endogenous silencing of spe-
cific genes, cells were transfected with 300 pmol of
E-cadherin-/Slug-/MEK-/ERK-/control-siRNA using
lipofectamine-2000 separately for 12 h. The mRNA
and protein levels were determined by RT-PCR and
western blotting, respectively [69]80.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a ChIP assay kit
(Millipore, Darmstadt, Germany) according to the man-
ufacturer’s instructions. PCR assay for identification of
p-Elk-1 and NFκB binding regions on SLUG promoter



























Extracted DNA (2 μl) was used for 45 cycles of ampli-
fication in 50 μl of reaction mixture under the following
conditions: 95 °C for 30s, 56 °C for 30s, and 72 °C for 60
s. The PCR products were analysed by 2 % agarose gel
electrophoresis [70]81.
Statistical analysis
Values are shown as standard error of mean, except
otherwise indicated. Data were analyzed and, appropri-
ate, significance (p < 0.05) of the differences between
mean values was determined by a Student’s t test.
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